Preserving Clinical Trial Integrity During the Coronavirus Pandemic

Preserving Clinical Trial Integrity During the Coronavirus Pandemic

This Viewpoint discusses ways the coronavirus pandemic is threatening clinical trial conduct and enrollment, and suggests ways to adapt, including changes to how outcomes data are collected and how interventions are delivered and monitored, to minimize trial disruption, maximize trial benefit, and e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2020-06, Vol.323 (21), p.2135-2136
Hauptverfasser: McDermott, Mary M, Newman, Anne B
Format: Artikel
Sprache:eng
Schlagworte:
Appointments and Schedules
Betacoronavirus
Cell Phone
Clinical trials
Coronavirus Infections - epidemiology
Coronavirus Infections - prevention & control
Coronaviruses
COVID-19
Electronic Mail
Guidelines as Topic
Humans
Intention to Treat Analysis
Medical Staff
Pandemics
Pandemics - prevention & control
Patient Safety
Pneumonia, Viral - epidemiology
Pneumonia, Viral - prevention & control
Quality Control
Randomized Controlled Trials as Topic - standards
Randomized Controlled Trials as Topic - statistics & numerical data
Risk Assessment
SARS-CoV-2
Surveys and Questionnaires
Transportation of Patients - methods
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This Viewpoint discusses ways the coronavirus pandemic is threatening clinical trial conduct and enrollment, and suggests ways to adapt, including changes to how outcomes data are collected and how interventions are delivered and monitored, to minimize trial disruption, maximize trial benefit, and ensure patient health and safety during the pandemic.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2020.4689